Swedish Orphan Biovitrum Ab · OMXSTO:SOBI
Swedish Orphan Biovitrum Ab — Shareholder Meeting (May 2022)
13 slides from Swedish Orphan Biovitrum Ab's shareholder meeting presentation, May 10, 2022
Slide 1: Annual General Meeting 2022
Swedish Orphan Biovitrum AB (publ) Annual General Meeting 2022 CEO presentation 10 May 2022
Slide 2: Forward-looking statements
Forward-looking statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) (Sobi®) is providing the following cautionary statement: This presentation contains forward-looking statements with re
Slide 3: Sobi's strategic goals remain unchanged
Sobi’s strategic goals remain unchanged Capture the Lead in Grow Go global value of our Haematology Immunology pipeline 6
Slide 4: 2021: revenue and EBITA delivered in line with outlook
2021: revenue and EBITA delivered in line with outlook Q4 Q4 FY FY Amounts in SEK M 2021 2020 Change 2021 2020 Change Total revenue (SEK M) (2020 in comparison) Total revenue 4,896 4,581 7% 15,529 15,261 2% Specialty Care Immunology Haematology Gross profit 3,880 3,718 4% 12,045 12,036 0% Gross marg
Slide 5: 2021: solid growth with increased diversification across disease areas and regions
2021: solid growth with increased diversification across both the disease areas and global regions Q4 ’21 change ratio FY ’21 change ratio Q4 ’21 change ratio FY ’21 change ratio SEK M % % SEK M % % SEK M % % SEK M % % Haematology 2,242 8 46 8,536 3 55 Europe 1,806 6 37 7,011 -5 45 – Haemophilia 1,9
Slide 6: 2022 Q1: a good start
2022 Q1: a good start • Revenue up 24%, incl. phasing of Doptelet® sales to China +24% • Launch medicines1 up 126% Q1 2022 revenue • EBITA margin 26%, incl. provision for expected credit losses in Russia and restruc- turing (contract manufacturing closure, site simplification, efficiency programmes)
Slide 7: 2022 Q1: revenue, EBITA margin adjusted underpin outlook
2022 Q1: revenue, EBITA margin adjusted underpin outlook Q1 Q1 Full-year Total revenue (SEK M) 2022 2021 Change 2021 Total revenue 4,925 3,661 35% 15,529 Haematology Immunology Specialty Care Gross profit 3,409 2,935 16% 12,045 4 896 4 925 Gross margin1 69% 80% 78% 324 307 EBITA1 1,290 1,484 -13% 5,
Slide 8: 2022 Q1: net debt - continued strong cash generation
2022 Q1: net debt - continued strong cash generation Absolute amounts in SEK million and at actual exchange rates. 11
Slide 9: 2022 outlook
2022 outlook Revenue Anticipated to grow by a mid to high single-digit percentage at CER1 EBITA margin Anticipated to be at a low 30s percentage of revenue (now based on EBITA margin adjusted2) 1. Constant exchange rates 2. Excluding items affecting comparability. 12
Slide 10: Pipeline: future growth
@sobl Pipeline: future growth Phase 1 | Phase 2 | Phase 3 Registration Aspaveli/Empaveli BIVV001 (efanesoctocog alfa) Doptelet (avatrombopag) (pegcetacoplan) Haemophilia A Chronic liver disease Transplant-associated thrombotic microangiopathy after allogenic Gamifant (emapalumab) Aspaveli/Empaveli h
Slide 11: Pipeline: continued news flow
Pipeline: continued news flow Anticipated major upcoming pipeline news flow H1 2022 H2 2022 2023 Aspaveli/Empaveli – IC-MPGN and Efanesoctocog alfa – haemophilia Efanesoctocog alfa – haemophilia A C3G1: phase 3 study first patient A: regulatory submission (US) (by (paediatric): XTEND-Kids phase 3 do
Slide 12: Sustainability: we have established a strong strategy, and our progress is recognised by external stakeholders
Sustainability: we have established a strong strategy, and our progress is recognised by external stakeholders Commitment to Responsible A positive momentum in most major analyst patients behaviour evaluations Rating 2021 2020 2019 MSCI A A A Our R&D is ethical and We help our people focused on medi
Slide 13: Sustainability: examples of our progress in 2021
Sustainability: examples of our progress in 2021 Commitment to patients Responsible behaviour programmes in rare 5 novel mechanisms of Overall gender 2021 2020 10 diseases action composition % F M F M Board 50 50 38 62 59% 41% Exec Comm Senior mgmt1 8 40 92 60 18 42 82 58 Responsible sourcing 67% 10
Swedish Orphan Biovitrum — Shareholder Meeting (May 2022) on 6ix